Routes of administration By mouth
Drug class Atypical antipsychotic
Pharmacokinetic data
Bioavailability 4.4%
Protein binding 97.4%
Metabolism Multiple UGTs, CYP450s, and AKR enzymes
Excretion <1% excreted unchanged in urine
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the pyridopyrroloquinoxaline and butyrophenone families.
Lumateperone has a multimodal mechanism, modulating dopamine, serotonin, and glutamate.
Dopamine: presynaptic partial agonist and postsynaptic antagonist at D2 receptors, with relatively low overall D2 occupancy and mesolimbic selectivity (≈40% D2 occupancy vs 60–80% for many SGAs), which is thought to lower EPS risk.
Serotonin: very high‑affinity 5‑HT2A antagonism (≈60× higher affinity than for D2) plus serotonin transporter (SERT) inhibition, giving antidepressant and pro‑cognitive effects.
Glutamate: indirect enhancement of NMDA receptor–mediated glutamatergic transmission via D1‑linked pathways, potentially relevant for negative and cognitive symptoms.
Lumateperone (Caplyta) is an oral second‑generation (atypical) antipsychotic approved in adults for schizophrenia, bipolar I/II depression (monotherapy or with lithium/valproate), and as adjunctive therapy for major depressive disorder with an antidepressant.
Lumateperone is indicated for the treatment of schizophrenia in adults; and depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate.
Approved lumateperone for the treatment of bipolar depression in adults as monotherapy and as adjunctive therapy with lithium or valproate, the treatment of major depressive disorder in adults as an adjunctive therapy with an oral antidepressant.
The most common adverse effects (≥5%) were somnolence and dry mouth.
Lumateperone is associated with a low rate of serum aminotransferase elevations during therapy, but has not been linked to instances of clinically apparent acute liver injury.
Lumateperone acts as an antagonist at 5-HT2A receptors and binds to several dopamine receptors (D1, D2, and D4) with moderate affinity.
It has moderate serotonin transporter reuptake inhibition, which is partly responsible for its antidepressant effect in bipolar disorder and reduction of negative symptoms of schizophrenia.
It may also inhibit dopamine transporter reuptake.
It has additional off-target antagonism at α1 receptors, without appreciable antimuscarinic or antihistaminergic properties, limiting side effects associated with other atypical antipsychotics, notably metabolic syndrome and hyperprolactinemia.
Similar to aripiprazole, lumateperone acts as a partial agonist at inhibitory D2 autoreceptors and an antagonist at postsynaptic D2 receptors, thereby simultaneously reducing dopamine release and binding to postsynaptic receptors, respectively.
Lumateperone only occupies around 39% of D2 receptors—compared to at least 60-80% D2 occupancy for most antipsychotics to work for psychosis and displays regioselectivity for the mesolimbic pathway, whose hyperactivity is responsible for the positive symptoms of schizophrenia.
This reduces the risk of extrapyramidal symptoms (EPS) from reduced dopaminergic transmission in the nigrostriatal pathway.
All atypical antipsychotics have pantagonism of 5HT2A receptors, but, uniquely, lumateperone’s affinity for these receptors is 60x higher than its affinity for D2 receptors.
This makes it a highly effective treatment for negative and cognitive symptoms of schizophrenia since 5HT2A antagonism increases dopamine release in the mesocortical pathway, which is hypoactive in those with schizophrenia.
Interestingly, lumateperone indirectly augments glutamatergic neurotransmission through its activity at D1 receptors, which causes phosphorylation of GluN2B subunits of NMDA receptors in the mesolimbic pathway.
This is significant since NMDA receptor hypofunction, reduced D1 binding, and glutamatergic abnormalities have been implicated in contributing to the cognitive and negative symptoms of schizophrenia.
It has also been identified as a potent vesicular monoamine transporter 2 (VMAT2) inhibitor.
Lumateperone reaches maximum plasma concentrations within 1–2 hours and has a terminal elimination half-life of 18 hours.
Lumateperone is a substrate for numerous metabolic enzymes, including various glucuronosyltransferase (UGT), aldo-keto reductase (AKR) isoforms and cytochrome P450 (CYP) enzymes (CYP3A4, 2C8, and 1A2).
Lumateperone does not cause appreciable inhibition of any common CYP450 enzymes.
The FDA approved lumateperone based on evidence from three clinical trials that enrolled 818 adult participants with schizophrenia.
In each trial, hospitalized participants with schizophrenia were randomly assigned to receive either lumateperone or a comparison treatment (placebo or active comparator) once daily for four weeks or six weeks.
Schizophrenia in adults: once‑daily oral capsule, with or without food; no routine titration required per current labeling.
Bipolar I or II depression in adults: monotherapy or adjunct to lithium/valproate, same once‑daily regimen.
Major depressive disorder (MDD): adjunctive use with an oral antidepressant in adults.
Commonly used capsule strength is 42 mg once daily; lower strengths exist for special situations such as hepatic impairment or strong CYP3A4 inhibitor co‑administration per label.
Schizophrenia: RCTs demonstrate significant total score reductions vs placebo, with effect sizes comparable to other SGAs and benefits on negative symptoms in some analyses.
Bipolar depression: trials show significant improvement in depressive symptom scales versus placebo as mono‑ or adjunctive therapy.
Major depressant diseasebadjunct: recent studies led to FDA approval as add‑on to antidepressants, with improved depressive symptoms versus antidepressant alone.
Overall profile is notable for relatively low metabolic and extrapyramidal symptom burden, though standard SGA class warnings still apply.
Common adverse effects:
Somnolence/sedation and dizziness.
Dry mouth, nausea, constipation, increased appetite or weight gain.
Orthostatic hypotension, particularly at initiation.
Serious risks and boxed warning:
Class boxed warning: increased mortality in elderly patients with dementia‑related psychosis; lumateperone is not approved in this population.
Suicidal thoughts and behaviors in young adults with mood disorders; monitor closely, especially early in treatment or during dose changes.
Neuroleptic malignant syndrome, tardive dyskinesia, leukopenia/neutropenia, orthostatic hypotension/syncope, and seizures, as with other second generation antidepressants.
Minimal prolactin elevation and relatively low rates of EPS and akathisia in trials compared with several other antipsychotics.
Metabolic effects:
Trials report placebo‑like changes in weight, lipids, and glycemia overall.
Administration: once daily, with or without food, swallow capsules whole.
Metabolism: primarily via CYP3A4; avoid strong CYP3A4 inducers, and adjust dose with strong CYP3A4 inhibitors or in moderate/severe hepatic impairment per label.
Monitoring: weight, BMI, waist circumference, fasting glucose and lipids, CBC, extrapyramidal symptoms, and suicidality, similar to other SGAs (second generation antipsychotics),
|